will provide select diagnostic tools from Berkeley HeartLab
’s (BHL) menu of cardiovascular tests and services. The co-marketing agreement includes BHL’s 4myheart cardiovascular disease management program.
Proven Diagnostics will be the first external clinical laboratory to have access to KIF6, BHL’s genetic test. The KIF6 gene encodes kinesin-like protein 6 (KIF6), which is thought to be associated with cardiovascular risk and statin benefit. Testing under the agreement will be performed by BHL.